Bone and prostate cancer cell interactions in metastatic prostate cancer

BJU International

Volumn 99, Issue 4, 2007, Pages 735-742

  Vela, Ian ^a,b   Gregory, Laura ^c   Gardiner, Edith M ^a,b   Clements, Judith A ^c   Nicol, David L ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Bone; Cancer; Cross talk; Metastasis; Prostate

Indexed keywords

ANDROGEN; BONE MORPHOGENETIC PROTEIN; ESTROGEN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

BONE AGE; BONE CANCER; BONE REMODELING; BONE STRUCTURE; CANCER CELL; CELL INTERACTION; HUMAN; METASTASIS; MICROENVIRONMENT; MOLECULAR BIOLOGY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

AGING; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; CELL COMMUNICATION; HORMONES; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 33947328871     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06670.x     Document Type: Short Survey

References (35)

1. Loberg RD, Gayed BA, Olson KB, Pienta KJ. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005; 96: 439-46
2. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease, 7th edn. Philadelphia, PA: Elsevier Saunders, 2005
3. Browner BD. Skeletal Trauma Basic Science, Management, and Reconstruction, 3rd edn. Philadelphia, PA: Saunders; 2003
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64
5. Alexandre C. Androgens and bone metabolism. Joint Bone Spine 2005; 72: 202-6
6. Kung AW. Androgen and bone mass in men. Asian J Androl 2003; 5: 148-54
7. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8
8. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005; 65: 7554-60
9. Hall CL, Kang S, MacDougald OA, Keller ET. Role of wnts in prostate cancer bone metastases. J Cell Biochem 2006; 97: 661-72
10. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005; 205: 130-44
11. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004; 75: 100-9
12. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001; 16: 1642-50
13. Oh KW, Rhee EJ, Lee WY et al. Circulating osteoprotegerin and receptor activator of NF-κB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 2005; 62: 92-8
14. Khosla S. Role of hormonal changes in the pathogenesis of osteoporosis in men. Calcif Tissue Int 2004; 75: 110-3
15. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 2005; 15: 23-7
16. Edlund M, Sung SY, Chung LW. Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem 2004; 91: 686-705
17. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003; 21: 392-8
18. Keller ET, Zhang J, Cooper CR et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 333-49
19. De S, Chen J, Narizhneva NV et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003; 278: 39044-50
20. Engl T, Relja B, Marian D et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 Integrins. Neoplasia 2006; 8: 290-301
21. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138: 1145-50
22. Bogdanos J, Karamanolakis D, Tenta R et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003; 10: 279-89
23. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001; 11: 483-8
24. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004; 91: 718-29
25. Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003; 12(Suppl. 2): S37-44
26. Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 2003; 29: 189-98
27. Nemeth JA, Yousif R, Herzog M et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17-25
28. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312
29. Nadiminty N, Lou W, Lee SO et al. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 2006; 12: 1420-30
30. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor ?B Fc diminishes prostate cancer progression in bone. Cancer Res 2003; 63: 7883-90
31. Meinbach DS, Lokeshwar BL. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urol Oncol 2006; 24: 294-306
32. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res 2003; 415 (Suppl.): S67-74
33. Kitagawa Y, Dai J, Zhang J et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005; 65: 10921-9
34. Chirgwin JM, Guise TA. Does prostate-specific antigen contribute to bone metastases? Clin Cancer Res 2006; 12: 1395-7
35. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-91